
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
C. Garrett Rappazzo, Longping V. Tse, Chengzi I. Kaku, et al.
Science (2021) Vol. 371, Iss. 6531, pp. 823-829
Open Access | Times Cited: 352
C. Garrett Rappazzo, Longping V. Tse, Chengzi I. Kaku, et al.
Science (2021) Vol. 371, Iss. 6531, pp. 823-829
Open Access | Times Cited: 352
Showing 1-25 of 352 citing articles:
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Delphine Planas, Nell Saunders, Piet Maes, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 671-675
Open Access | Times Cited: 1460
Delphine Planas, Nell Saunders, Piet Maes, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 671-675
Open Access | Times Cited: 1460
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Lihong Liu, Sho Iketani, Yicheng Guo, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 676-681
Open Access | Times Cited: 1268
Lihong Liu, Sho Iketani, Yicheng Guo, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 676-681
Open Access | Times Cited: 1268
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 593-602
Open Access | Times Cited: 1226
Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 593-602
Open Access | Times Cited: 1226
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 993
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 993
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen, Xianwen Zhang, James Brett Case, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 717-726
Open Access | Times Cited: 974
Rita E. Chen, Xianwen Zhang, James Brett Case, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 717-726
Open Access | Times Cited: 974
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Sho Iketani, Lihong Liu, Yicheng Guo, et al.
Nature (2022) Vol. 604, Iss. 7906, pp. 553-556
Open Access | Times Cited: 791
Sho Iketani, Lihong Liu, Yicheng Guo, et al.
Nature (2022) Vol. 604, Iss. 7906, pp. 553-556
Open Access | Times Cited: 791
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Qian Wang, Yicheng Guo, Sho Iketani, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 603-608
Open Access | Times Cited: 716
Qian Wang, Yicheng Guo, Sho Iketani, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 603-608
Open Access | Times Cited: 716
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1171-1187.e20
Open Access | Times Cited: 629
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1171-1187.e20
Open Access | Times Cited: 629
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen, et al.
Science (2022) Vol. 375, Iss. 6583, pp. 864-868
Open Access | Times Cited: 510
Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen, et al.
Science (2022) Vol. 375, Iss. 6583, pp. 864-868
Open Access | Times Cited: 510
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 506
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 506
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Cell Reports (2022) Vol. 39, Iss. 7, pp. 110812-110812
Open Access | Times Cited: 402
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Cell Reports (2022) Vol. 39, Iss. 7, pp. 110812-110812
Open Access | Times Cited: 402
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 373
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 373
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 311
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 311
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Timothée Bruel, Jérôme Hadjadj, Piet Maes, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1297-1302
Open Access | Times Cited: 290
Timothée Bruel, Jérôme Hadjadj, Piet Maes, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1297-1302
Open Access | Times Cited: 290
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
Science (2021) Vol. 374, Iss. 6575, pp. 1621-1626
Open Access | Times Cited: 289
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
Science (2021) Vol. 374, Iss. 6575, pp. 1621-1626
Open Access | Times Cited: 289
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 283
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 283
Broad sarbecovirus neutralization by a human monoclonal antibody
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 103-108
Open Access | Times Cited: 276
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 103-108
Open Access | Times Cited: 276
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
Andrea L. Cathcart, Colin Havenar‐Daughton, Florian A. Lempp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 243
Andrea L. Cathcart, Colin Havenar‐Daughton, Florian A. Lempp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 243
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 215
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 215
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases
Rita M. Meganck, Ralph S. Baric
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 401-410
Open Access | Times Cited: 201
Rita M. Meganck, Ralph S. Baric
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 401-410
Open Access | Times Cited: 201
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 199
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 199
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Lingshu Wang, Tongqing Zhou, Yi Zhang, et al.
Science (2021) Vol. 373, Iss. 6556
Open Access | Times Cited: 196
Lingshu Wang, Tongqing Zhou, Yi Zhang, et al.
Science (2021) Vol. 373, Iss. 6556
Open Access | Times Cited: 196
Prolonged evolution of the human B cell response to SARS-CoV-2 infection
Mrunal Sakharkar, C. Garrett Rappazzo, Wendy Wieland‐Alter, et al.
Science Immunology (2021) Vol. 6, Iss. 56
Open Access | Times Cited: 187
Mrunal Sakharkar, C. Garrett Rappazzo, Wendy Wieland‐Alter, et al.
Science Immunology (2021) Vol. 6, Iss. 56
Open Access | Times Cited: 187
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
David R. Martinez, Alexandra Schäfer, Sarah R. Leist, et al.
Science (2021) Vol. 373, Iss. 6558, pp. 991-998
Open Access | Times Cited: 180
David R. Martinez, Alexandra Schäfer, Sarah R. Leist, et al.
Science (2021) Vol. 373, Iss. 6558, pp. 991-998
Open Access | Times Cited: 180
Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
Jingwen Ai, Xun Wang, Xinyi He, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1077-1083.e4
Open Access | Times Cited: 171
Jingwen Ai, Xun Wang, Xinyi He, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1077-1083.e4
Open Access | Times Cited: 171